The effect of IFN-beta on these cells is unique as it also increased both absolute numbers and proportions of HLA-DR+ CD4+ and CD8+ T cells in the blood, arguing for a drug-specific effect that may not be beneficial for MS. This evidence concerns the gene CD8A and myeloid sarcoma.